{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:27:43Z","timestamp":1790724463041,"version":"4.1.0"},"reference-count":151,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222489\/Z\/21\/Z"],"award-info":[{"award-number":["222489\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["EP\/R024804\/1"],"award-info":[{"award-number":["EP\/R024804\/1"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["EP\/S012265\/1"],"award-info":[{"award-number":["EP\/S012265\/1"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["R01AI134091"],"award-info":[{"award-number":["R01AI134091"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["R24AI118397"],"award-info":[{"award-number":["R24AI118397"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["2020-38-LONGEVITY"],"award-info":[{"award-number":["2020-38-LONGEVITY"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EPSRC","award":["222489\/Z\/21\/Z"],"award-info":[{"award-number":["222489\/Z\/21\/Z"]}]},{"name":"EPSRC","award":["EP\/R024804\/1"],"award-info":[{"award-number":["EP\/R024804\/1"]}]},{"name":"EPSRC","award":["EP\/S012265\/1"],"award-info":[{"award-number":["EP\/S012265\/1"]}]},{"name":"EPSRC","award":["R01AI134091"],"award-info":[{"award-number":["R01AI134091"]}]},{"name":"EPSRC","award":["R24AI118397"],"award-info":[{"award-number":["R24AI118397"]}]},{"name":"EPSRC","award":["2020-38-LONGEVITY"],"award-info":[{"award-number":["2020-38-LONGEVITY"]}]},{"name":"NIH","award":["222489\/Z\/21\/Z"],"award-info":[{"award-number":["222489\/Z\/21\/Z"]}]},{"name":"NIH","award":["EP\/R024804\/1"],"award-info":[{"award-number":["EP\/R024804\/1"]}]},{"name":"NIH","award":["EP\/S012265\/1"],"award-info":[{"award-number":["EP\/S012265\/1"]}]},{"name":"NIH","award":["R01AI134091"],"award-info":[{"award-number":["R01AI134091"]}]},{"name":"NIH","award":["R24AI118397"],"award-info":[{"award-number":["R24AI118397"]}]},{"name":"NIH","award":["2020-38-LONGEVITY"],"award-info":[{"award-number":["2020-38-LONGEVITY"]}]},{"name":"Unitaid","award":["222489\/Z\/21\/Z"],"award-info":[{"award-number":["222489\/Z\/21\/Z"]}]},{"name":"Unitaid","award":["EP\/R024804\/1"],"award-info":[{"award-number":["EP\/R024804\/1"]}]},{"name":"Unitaid","award":["EP\/S012265\/1"],"award-info":[{"award-number":["EP\/S012265\/1"]}]},{"name":"Unitaid","award":["R01AI134091"],"award-info":[{"award-number":["R01AI134091"]}]},{"name":"Unitaid","award":["R24AI118397"],"award-info":[{"award-number":["R24AI118397"]}]},{"name":"Unitaid","award":["2020-38-LONGEVITY"],"award-info":[{"award-number":["2020-38-LONGEVITY"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, baricitinib), others failed to show clinical efficacy. One reason is the lack of clear translational processes based on adequate preclinical profiling before clinical evaluation. Combined with limitations of existing in vitro and in vivo models, there is a need for a systematic approach to urgent antiviral drug development in the context of a global pandemic. We implemented a methodology to test repurposed and experimental drugs to generate robust preclinical evidence for further clinical development. This translational drug development platform comprises in vitro, ex vivo, and in vivo models of SARS-CoV-2, along with pharmacokinetic modeling and simulation approaches to evaluate exposure levels in plasma and target organs. Here, we provide examples of identified repurposed antiviral drugs tested within our multidisciplinary collaboration to highlight lessons learned in urgent antiviral drug development during the COVID-19 pandemic. Our data confirm the importance of assessing in vitro and in vivo potency in multiple assays to boost the translatability of pre-clinical data. The value of pharmacokinetic modeling and simulations for compound prioritization is also discussed. We advocate the need for a standardized translational drug development platform for mild-to-moderate COVID-19 to generate preclinical evidence in support of clinical trials. We propose clear prerequisites for progression of drug candidates for repurposing into clinical trials. Further research is needed to gain a deeper understanding of the scope and limitations of the presented translational drug development platform.<\/jats:p>","DOI":"10.3390\/microorganisms10081639","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T03:33:20Z","timestamp":1660534400000},"page":"1639","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1146-3452","authenticated-orcid":false,"given":"Frauke","family":"Assmus","sequence":"first","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2326-2938","authenticated-orcid":false,"given":"Jean-S\u00e9lim","family":"Driouich","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Institut de Recherche pour le D\u00e9veloppement (IRD), Aix-Marseille University, 190-Inserm 1207, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-7312","authenticated-orcid":false,"given":"Rana","family":"Abdelnabi","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8820-6617","authenticated-orcid":false,"given":"Laura","family":"Vangeel","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-2249","authenticated-orcid":false,"given":"Franck","family":"Touret","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Institut de Recherche pour le D\u00e9veloppement (IRD), Aix-Marseille University, 190-Inserm 1207, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayorinde","family":"Adehin","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3839-9777","authenticated-orcid":false,"given":"Palang","family":"Chotsiri","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Cochin","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Institut de Recherche pour le D\u00e9veloppement (IRD), Aix-Marseille University, 190-Inserm 1207, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S.","family":"Foo","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-6028","authenticated-orcid":false,"given":"Dirk","family":"Jochmans","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungtaek","family":"Kim","sequence":"additional","affiliation":[{"name":"Institut Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si 13488, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-5957","authenticated-orcid":false,"given":"L\u00e9a","family":"Luciani","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Institut de Recherche pour le D\u00e9veloppement (IRD), Aix-Marseille University, 190-Inserm 1207, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Moureau","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Institut de Recherche pour le D\u00e9veloppement (IRD), Aix-Marseille University, 190-Inserm 1207, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-320X","authenticated-orcid":false,"given":"Soonju","family":"Park","sequence":"additional","affiliation":[{"name":"Institut Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si 13488, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4743-3626","authenticated-orcid":false,"given":"Paul-R\u00e9mi","family":"P\u00e9tit","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Institut de Recherche pour le D\u00e9veloppement (IRD), Aix-Marseille University, 190-Inserm 1207, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shum","sequence":"additional","affiliation":[{"name":"Institut Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si 13488, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanaporn","family":"Wattanakul","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-6303","authenticated-orcid":false,"given":"Birgit","family":"Weynand","sequence":"additional","affiliation":[{"name":"Departmet of Imaging and Pathology, Katholieke Universiteit Leuven, Translational Cell and Tissue Research, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fraisse","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative (DND<i>i<\/i>), 1202 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Robert","family":"Ioset","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative (DND<i>i<\/i>), 1202 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Mowbray","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative (DND<i>i<\/i>), 1202 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-7651","authenticated-orcid":false,"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Centre for Excellence in Long-Acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 7ZX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Hoglund","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier de","family":"Lamballerie","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Institut de Recherche pour le D\u00e9veloppement (IRD), Aix-Marseille University, 190-Inserm 1207, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Nougair\u00e8de","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Institut de Recherche pour le D\u00e9veloppement (IRD), Aix-Marseille University, 190-Inserm 1207, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-7514","authenticated-orcid":false,"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium"},{"name":"Global Virus Network (GVN), Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6768-0536","authenticated-orcid":false,"given":"Peter","family":"Sj\u00f6","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative (DND<i>i<\/i>), 1202 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9177-9755","authenticated-orcid":false,"given":"Fanny","family":"Escudi\u00e9","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative (DND<i>i<\/i>), 1202 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-9289","authenticated-orcid":false,"given":"Ivan","family":"Scandale","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative (DND<i>i<\/i>), 1202 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative (DND<i>i<\/i>), 1202 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"ref_1","first-page":"e7386","article-title":"Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2","volume":"12","author":"Valencia","year":"2020","journal-title":"Cureus"},{"key":"ref_2","unstructured":"(2022, April 14). WHO Director-General\u2019s Opening Remarks at the Media Briefing on COVID-19. Available online: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020."},{"key":"ref_3","unstructured":"(2022, June 15). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_4","unstructured":"(2022, April 14). COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available online: https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"ref_5","unstructured":"World Health Organization (2022, May 05). Press Release. 14.9 Million Excess Deaths Associated with the COVID-19 Pandemic in 2020 and 2021. Available online: https:\/\/www.who.int\/news\/item\/05-05-2022-14.9-million-excess-deaths-were-associated-with-the-covid-19-pandemic-in-2020-and-2021."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19 and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_9","unstructured":"(2022, April 14). COVID-19 Clinical Research Coalition. Available online: https:\/\/covid19crc.org\/."},{"key":"ref_10","unstructured":"ANTICOV Consortium (2022, May 05). ANTICOV Clinical Trial. Available online: https:\/\/anticov.org\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1343228","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"Tobinick","year":"2009","journal-title":"Drug News Perspect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03256811","article-title":"Repurposing Strategies for Therapeutics","volume":"24","author":"Sleigh","year":"2010","journal-title":"Pharm. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/imt-2021-0168","article-title":"A global picture: Therapeutic perspectives for COVID-19","volume":"14","author":"Chavda","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"Novac","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"588654","DOI":"10.3389\/fphar.2020.588654","article-title":"Challenges for Drug Repurposing in the COVID-19 Pandemic Era","volume":"11","author":"Sultana","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41392-020-0190-2","article-title":"Overview of lethal human coronaviruses","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target, Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug Repurposing for Viral Infectious Diseases: How Far Are We?","volume":"26","author":"Mercorelli","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kim, W.Y., Kweon, O.J., Cha, M.J., Baek, M.S., and Choi, S.H. (2021). Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0254167"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/d41586-020-01824-5","article-title":"Coronavirus breakthrough: Dexamethasone is first drug shown to save lives","volume":"582","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"o573","DOI":"10.1136\/bmj.o573","article-title":"COVID-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial","volume":"376","author":"Mahase","year":"2022","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11239-022-02643-3","article-title":"Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: Updated clinical guidance from the anticoagulation forum","volume":"54","author":"Barnes","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_23","unstructured":"(2022, August 02). National Institutes of Health COVID-19 Treatment Guidelines. Antithrombotic Therapy in Patients with COVID-19, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antithrombotic-therapy\/."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Rannard, S.P., McDonald, T.O., and Owen, A. (2020). Chasing COVID-19 chemotherapeutics without putting the cart before the horse. Br. J. Clin. Pharmacol.","DOI":"10.22541\/au.159413561.14757083"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Homayouni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","article-title":"Drug combination therapy for emerging viral diseases","volume":"26","author":"Shyr","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/bcp.15089","article-title":"Combination therapies for COVID-19: An overview of the clinical trials landscape","volume":"88","author":"Akinbolade","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/cpt.2099","article-title":"Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development","volume":"110","author":"Boffito","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/cpt.1909","article-title":"Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics","volume":"108","author":"Arshad","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.12688\/f1000research.53275.2","article-title":"Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day","volume":"10","author":"Eugene","year":"2022","journal-title":"F1000Research"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jviromet.2005.05.010","article-title":"Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus","volume":"129","author":"Ivens","year":"2005","journal-title":"J. Virol. Methods"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105122","DOI":"10.1016\/j.antiviral.2021.105122","article-title":"A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents","volume":"192","author":"Do","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_34","unstructured":"(2022, June 15). Drugs for Neglected Diseases Intitiative. Target Product Profile for COVID-19. Available online: https:\/\/dndi.org\/diseases\/covid-19\/target-product-profile\/."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41467-022-28354-0","article-title":"The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern","volume":"13","author":"Abdelnabi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1038\/s41467-020-19684-y","article-title":"STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters","volume":"11","author":"Boudewijns","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","author":"Driouich","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wattanakul, T., Chotsiri, P., Scandale, I., Hoglund, R.M., and Tarning, J. (Expert Rev. Clin. Pharmacol., 2022). Pharmacometric approach to evaluate drug for potential repurposing as COVID-19 therapeutics, Expert Rev. Clin. Pharmacol., submitted.","DOI":"10.1080\/17512433.2022.2113388"},{"key":"ref_40","unstructured":"Lavielle, M. (2022, June 15). mlxR: Simulation of Longitudinal Data. R Package Version 4.2.0. Available online: https:\/\/cran.r-project.org\/web\/packages\/mlxR\/index.html."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamainternmed.2021.6759","article-title":"Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial","volume":"182","author":"Clemency","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41551-021-00718-9","article-title":"A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics","volume":"5","author":"Si","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102367","DOI":"10.1016\/j.isci.2021.102367","article-title":"Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment","volume":"24","author":"Ohashi","year":"2021","journal-title":"iScience"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"105311","DOI":"10.1016\/j.antiviral.2022.105311","article-title":"HIV protease inhibitors Nelfinavir and Lopinavir\/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect","volume":"202","author":"Foo","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2217\/fmb-2019-0231","article-title":"Clofazimine: An old drug for never-ending diseases","volume":"15","author":"Riccardi","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2","volume":"593","author":"Yuan","year":"2021","journal-title":"Nature"},{"key":"ref_49","unstructured":"Fujifilm Press Release (2022, June 24). Anti-Influenza Drug Avigan\u00ae Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 Patients. Available online: https:\/\/www.fujifilm.com\/jp\/en\/news\/hq\/5451."},{"key":"ref_50","unstructured":"Merck Press Release (2022, June 24). Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO\u2122 (Molnupiravir) Was Associated with More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo. Available online: https:\/\/www.merck.com\/news\/merck-and-ridgeback-to-present-data-demonstrating-that-treatment-with-lagevrio-molnupiravir-was-associated-with-more-rapid-elimination-of-infectious-sars-cov-2-than-placebo\/."},{"key":"ref_51","unstructured":"Pfizer Press Release (2022, June 24). Pfizer Announces Additional Phase 2\/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-additional-phase-23-study-results."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Burrell, C.J., Howard, C.R., and Murphy, F.A. (2017). Classification of Viruses and Phylogenetic Relationships. Fenner White\u2019s Med. Virol., 15\u201325.","DOI":"10.1016\/B978-0-12-375156-0.00002-3"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.chom.2020.09.017","article-title":"Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics","volume":"28","author":"Grobler","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coph.2021.11.002","article-title":"Treatments for COVID-19: Lessons from 2020 and new therapeutic options","volume":"62","author":"Salasc","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","article-title":"Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2","volume":"585","author":"Hoffmann","year":"2020","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","article-title":"Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity","volume":"65","author":"Hoffmann","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2901-9","article-title":"Identification of SARS-CoV-2 inhibitors using lung and colonic organoids","volume":"589","author":"Han","year":"2021","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e00825-20","DOI":"10.1128\/AAC.00825-20","article-title":"Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production","volume":"64","author":"Sacramento","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Yamamoto, N., Matsuyama, S., Hoshino, T., and Yamamoto, N. (2020). Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv.","DOI":"10.1101\/2020.04.06.026476"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2217\/fon-2020-0571","article-title":"The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer","volume":"16","author":"Mollica","year":"2020","journal-title":"Future Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1476-5381.2010.00801.x","article-title":"Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport","volume":"160","author":"Ambroziak","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/science.abi4708","article-title":"Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2","volume":"373","author":"Tummino","year":"2021","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"108959","DOI":"10.1016\/j.celrep.2021.108959","article-title":"Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2","volume":"35","author":"Dittmar","year":"2021","journal-title":"Cell Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e105114","DOI":"10.15252\/embj.20105114","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells","volume":"39","author":"Lukassen","year":"2020","journal-title":"EMBO J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_66","unstructured":"Atea Pharmaceuticals Press Release (2022, June 24). Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting. Available online: https:\/\/ir.ateapharma.com\/news-releases\/news-release-details\/atea-pharmaceuticals-provides-update-and-topline-results-phase-2."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/17425255.2.5.715","article-title":"Preclinical formulations for discovery and toxicology: Physicochemical challenges","volume":"2","author":"Neervannan","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2021.06.004","article-title":"Clinical Management of COVID-19 Patients\u2014An Update","volume":"52","author":"Agergaard","year":"2022","journal-title":"Semin. Nucl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.7861\/clinmed.2020-0524","article-title":"Antiviral treatment for COVID-19: The evidence supporting remdesivir","volume":"20","author":"Richardson","year":"2020","journal-title":"Clin. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e02479-20","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.abh3996","article-title":"COVID-19 lessons for research","volume":"371","author":"Collins","year":"2021","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/d41573-021-00068-w","article-title":"RECOVERY 1 year on: A rare success in the COVID-19 clinical trial landscape","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials","volume":"12","author":"Axfors","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/jac\/dkab433","article-title":"Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: A randomized double-blind clinical trial (DISCOVER)","volume":"77","author":"Mobarak","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jiph.2021.03.015","article-title":"Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials","volume":"14","author":"Patel","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Acharya, B.N. (2020). Amodiaquine as COVID-19 Mpro Inhibitor: A Theoretical Study. ChemRxiv.","DOI":"10.26434\/chemrxiv.12555137"},{"key":"ref_77","unstructured":"World Health Organization (2022, June 23). Tracking SARS-CoV-2 Variants. Available online: https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants."},{"key":"ref_78","unstructured":"World Health Organization (2022, May 05). Facilitation Council Preparation. Available online: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/act-accelerator\/act-a-tx-dx-fc-pre-briefing-deck_fin.pdf?sfvrsn=ce5b7dea_1&download=true."},{"key":"ref_79","unstructured":"World Health Organization (2022, June 15). Therapeutics and COVID-19: Living Guideline. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.3."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jviromet.2012.04.011","article-title":"A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE","volume":"183","author":"Jochmans","year":"2012","journal-title":"J. Virol. Methods"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"105137","DOI":"10.1016\/j.antiviral.2021.105137","article-title":"Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2","volume":"193","author":"Touret","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100059","DOI":"10.1016\/j.xcrm.2020.100059","article-title":"Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia","volume":"1","author":"Pizzorno","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/03009858211057197","article-title":"Hamster models of COVID-19 pneumonia reviewed: How human can they be?","volume":"59","author":"Gruber","year":"2022","journal-title":"Vet. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Francis, M.E., Goncin, U., Kroeker, A., Swan, C., Ralph, R., Lu, Y., Etzioni, A.L., Falzarano, D., Gerdts, V., and Machtaler, S. (2021). SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney. PLoS Pathog., 17.","DOI":"10.1101\/2021.04.07.438843"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"107940","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"103403","DOI":"10.1016\/j.ebiom.2021.103403","article-title":"Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters","volume":"68","author":"Abdelnabi","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s42003-022-03171-9","article-title":"The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model","volume":"5","author":"Cochin","year":"2022","journal-title":"Commun. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"105212","DOI":"10.1016\/j.antiviral.2021.105212","article-title":"Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model","volume":"197","author":"Cochin","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"104148","DOI":"10.1016\/j.ebiom.2022.104148","article-title":"Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2","volume":"82","author":"Driouich","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","article-title":"An automated sampling importance resampling procedure for estimating parameter uncertainty","volume":"44","author":"Dosne","year":"2017","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Ferreira Sales-Medina, D., Rodrigues Pinto Ferreira, L., Romera, L.M.D., Ribeiro Gon\u00e7alves, K., Guido, R.V.C., Courtemanche, G., Buckeridge, M.S., Durigon, E.L., Moraes, C.B., and Freitas-Junior, L.H. (2020). Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19. bioRxiv.","DOI":"10.1101\/2020.07.09.196337"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S.Y., Park, S., Shum, D., and Kim, S. (2020). Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00819-20"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkab072","article-title":"In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19","volume":"76","author":"Sacramento","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/jmv.26397","article-title":"Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells","volume":"93","author":"Ko","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e01218-20","DOI":"10.1128\/JVI.01218-20","article-title":"Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo","volume":"94","author":"Weston","year":"2020","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Liu, S., Lien, C.Z., Selvaraj, P., and Wang, T.T. (2020). Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection. BioRxiv.","DOI":"10.1101\/2020.04.29.067983"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e01652-20","DOI":"10.1128\/AAC.01652-20","article-title":"Repurposing Nucleoside Analogs for Human Coronaviruses","volume":"65","author":"Zandi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"106542","DOI":"10.1016\/j.ijantimicag.2022.106542","article-title":"Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2","volume":"59","author":"Jeffreys","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Xu, Z., Yao, H., Shen, J., Wu, N., Xu, Y., Lu, X., Zhu, W., and Li, L.-J. (2020). Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 Cells. ChemRxiv.","DOI":"10.26434\/chemrxiv.12039888"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1734-1140(11)70500-X","article-title":"Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions","volume":"63","author":"Rogosnitzky","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1038\/s41598-021-85049-0","article-title":"The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue","volume":"11","author":"Zimniak","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/22221751.2020.1829082","article-title":"Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine","volume":"9","author":"Schloer","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"755600","DOI":"10.3389\/fphar.2021.755600","article-title":"Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro","volume":"12","author":"Fred","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Olaleye, O.A., Kaur, M., and Onyenaka, C.C. (2020). Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein\u2019s Receptor Binding Domain and Recombinant Human ACE2. BioRxiv.","DOI":"10.1101\/2020.09.13.295691"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e2108728118","DOI":"10.1073\/pnas.2108728118","article-title":"A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells","volume":"118","author":"Mahoney","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-04482-x","article-title":"Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2","volume":"604","author":"Schultz","year":"2022","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","volume":"11","author":"Xiong","year":"2020","journal-title":"Protein Cell"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"103213","DOI":"10.1016\/j.isci.2021.103213","article-title":"6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro","volume":"24","author":"Swaim","year":"2021","journal-title":"iScience"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"668698","DOI":"10.3389\/fmed.2021.668698","article-title":"Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial","volume":"8","author":"McCoy","year":"2021","journal-title":"Front. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"18085","DOI":"10.1038\/s41598-021-97658-w","article-title":"Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro","volume":"11","author":"Murray","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Box, H., Pennington, S.H., Kijak, E., Tatham, L., Caygill, C.H., Lopeman, R.C., Jeffreys, L.N., Herriott, J., Sharp, J., and Neary, M. (2022). Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: A need for better understanding of inter-lab differences in preclinical assays. bioRxiv.","DOI":"10.1101\/2022.03.03.482788"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"106499","DOI":"10.1016\/j.ijantimicag.2021.106499","article-title":"Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice","volume":"59","author":"Muturi","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"103595","DOI":"10.1016\/j.ebiom.2021.103595","article-title":"The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model","volume":"72","author":"Abdelnabi","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e2021579118","DOI":"10.1073\/pnas.2021579118","article-title":"Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection","volume":"118","author":"Jan","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1038\/s41598-021-86679-0","article-title":"Ivermectin reduces in vivo coronavirus infection in a mouse experimental model","volume":"11","author":"Arevalo","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1472-8206.1994.tb00774.x","article-title":"Antimalarial 4-aminoquinolines: Mode of action and pharmacokinetics","volume":"8","author":"Pussard","year":"1994","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_128","unstructured":"(2022, July 01). Atazanavir PK Fact Sheet. Available online: https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/fact_sheets\/pdfs\/000\/000\/087\/original\/HIV_FactSheet_ATV_2016_Mar.pdf."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40262-017-0624-3","article-title":"Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics","volume":"57","author":"Gandhi","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","article-title":"The pharmacokinetics and interactions of ivermectin in humans\u2014A mini-review","volume":"10","year":"2008","journal-title":"AAPS J."},{"key":"ref_132","unstructured":"(2022, July 01). Romark Pharmaceuticals, Alinia\u00ae, Product Monograph, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/021818lbl.pdf."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1310\/hpj4905-466","article-title":"Sofosbuvir","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp. Pharm."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.phrs.2003.07.011","article-title":"Bioequivalence assessment of ambroxol tablet after a single oral dose administration to healthy male volunteers","volume":"49","author":"Lee","year":"2004","journal-title":"Pharmacol. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1128\/AAC.01242-12","article-title":"Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy","volume":"56","author":"Tarning","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijantimicag.2016.11.019","article-title":"Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients","volume":"49","author":"Punyawudho","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.jchromb.2010.08.026","article-title":"Simple, sensitive and rapid HPLC-MS\/MS method for the determination of cepharanthine in human plasma","volume":"878","author":"Hao","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3999\/jscpt.20.741","article-title":"Pharmacokinetic disposition of cepharanthin following single and multiple intravenous doses in healthy subjects","volume":"20","author":"Yasuda","year":"1989","journal-title":"Jpn. J. Clin. Pharmacol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3999\/jscpt.20.735","article-title":"Pharmacokinetic study of cepharanthin following single oral doses in healthy subjects","volume":"20","author":"Yasuda","year":"1989","journal-title":"Jpn. J. Clin. Pharmacol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e01905-19","DOI":"10.1128\/AAC.01905-19","article-title":"Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients","volume":"64","author":"Faraj","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s40262-016-0504-2","article-title":"Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection","volume":"56","author":"Chan","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"103125","DOI":"10.1016\/j.ebiom.2020.103125","article-title":"Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza","volume":"62","author":"Wang","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e00864","DOI":"10.1002\/prp2.864","article-title":"Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders","volume":"9","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2125.2009.03587.x","article-title":"Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure","volume":"69","author":"Orlando","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12936-017-1923-8","article-title":"Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles","volume":"16","author":"Kobylinski","year":"2017","journal-title":"Malar. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e02428-20","DOI":"10.1128\/AAC.02428-20","article-title":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1128\/AAC.01596-05","article-title":"Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: A population study with 133 women","volume":"50","author":"Hirt","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1111\/bcp.14619","article-title":"Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis","volume":"87","author":"Rajoli","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Balderas-Acata, J., Bueno, E., P\u00e9rez-Becerril, F., Espinosa-Mart\u00ednez, C., Burkefraga, V., and Gonz\u00e1lez-de la Parra, M. (2011). Bioavailability of Two Oral-Suspension Formulations of a Single Dose of Nitazoxanide 500 mg: An Open-Label, Randomized-Sequence, Two-Period Crossover, Comparison in Healthy Fasted Mexican Adult Volunteers. J. Bioequiv. Bioavailab., 3.","DOI":"10.4172\/jbb.1000056"},{"key":"ref_150","unstructured":"Jin, F., Kirby, B., Gao, Y., Kearney, B., and Mathias, A. (2022, July 01). Population Pharmacokinetic Modeling of Sofosbuvir, an NS5B Polymerase Inhibitor, and Its Metabolites in Patients with Hepatitis C Virus Infection, Poster presentation at PAGE-Meeting. 2015. Hersonissos, Crete, Greece. Available online: https:\/\/www.page-meeting.org\/pdf_assets\/3129-PAGE%20poster.pdf."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s43440-020-00132-z","article-title":"Cepharanthine: A review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19","volume":"72","author":"Rogosnitzky","year":"2020","journal-title":"Pharmacol. Rep."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/10\/8\/1639\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:08:09Z","timestamp":1760141289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/10\/8\/1639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":151,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["microorganisms10081639"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms10081639","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]}}}